Synavive (prednisolone/dipyridamole) - Sun Pharma
4 reasons to buy Zalicus (SeekingAlpha) - Aug 1, 2012 - Anticipated Synavive P2b results in Sep 2012; Synavive's estimated market potential $2B to $4B 
Anticipated P2b data • Sales projection • Rheumatoid Arthritis
http://seekingalpha.com/article/768931-4-reasons-to-buy-zalicus
 
Aug 1, 2012
 
Zalicus announced in April that it expected to report top-line results from its Synergy Phase II(b) clinical trial of Synavive in Rheumatoid Arthritis around the end of September 2012... In my opinion, Synavive's estimated market could be between $2 billion to $4 billion...